Revonto available for treating malignant hyperthermia

US WorldMeds announced that it has launched Revonto (dantrolene sodium for injection) for the management of fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises. Revonto is also indicated preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible. Compared to the original formulation of dantrolene sodium for injection, Revonto offers a shortened reconstitution time of approximately 20 seconds.

For more information call (888) 900-USWM or visit www.revonto.com.